Clinical value of propylthiouracil combined with levothyroxine sodium tablets in the treatment of benign multiple thyroid nodules
Objective:To investigate the clinical efficacy and prognosis of propyl thiouracil combined with levothyroxine sodium tablets in the treatment of benign multiple thyroid nodules.Methods:Eighty patients with benign multiple thyroid nodules who were treated in our hospital from August 2018 to August 2022 were randomly divided into a control group and a study group,with 40 cases in each group.The control group was treated with levothyroxine sodium tablets(25 μg·time-1,once·day-1);the study group was treated with propylthiouracil(initial dose of 150-400 mg·day-1,maintained at 50-100 mg·time-1,once·day-1)plus levothyroxine sodium tablets.After 6 months of treatment,the clinical efficacy of the two groups was compared.The free thyroxine(FT4),free triiodothyronine(FT3),and thyroid stimulating hormone(TSH)levels were measured using radioimmunoassay before and after treatment for 6 months.The thyroid nodule diameter and thyroid volume were measured using a GE Logiq E9 color Doppler ultrasound diagnostic instrument before and after treatment for 6 months.Adverse reactions during treatment were observed in two groups.Results:The total effective rate of the treatment group was significantly higher than that of the control group(P<0.05).The serum TSH level in the treatment group after treatment was lower than that in the control group(P<0.05),but there was no significant difference in the levels of FT3 and FT4 between the two groups(P>0.05).Compared with the control group,the diameter and volume of thyroid nodules in the treatment group after treatment were smaller(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Propyl thiouracil combined with levothyroxine sodium tablets in the treatment of benign multiple thyroid nodules can improve the therapeutic effect,improve the thyroid hormone level,inhibit the progression of nodules,and improve the prognosis.
万方数据
维普
